ELAN vs EXEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ELAN exhibits a critical divergence between market sentiment and fundamental health, highlighted by a very weak Piotroski F-Score of 2/9. While the company has seen a massive 1-year price surge of 140.5% and maintains strong analyst support (Strong Buy), the underlying financials show negative profit margins and negative ROE. Revenue growth remains positive at 12.2%, and the company consistently beats earnings estimates, but the high PEG ratio of 3.83 suggests the stock is significantly overvalued relative to its actual growth. The outlook is neutral as the market bets on a turnaround that the current deterministic health scores do not yet support.
EXEL shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
Compare Another Pair
Related Comparisons
ELAN vs EXEL: Head-to-Head Comparison
This page compares Elanco Animal Health Incorporated (ELAN) and Exelixis, Inc. (EXEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.